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Background/aim: The increasing number of lung diseases and particularly pulmonary malignancies has intensified the need for
diverse interventions in the field of interventional pulmonology. In recent years we have seen many new developments and expanding
applications in the field of interventional pulmonology. This has resulted in an increased number and variety of performed procedures
and differing approaches. The purpose of the present study is to provide information on patient characteristics, range of interventions,
complication rates, and the evolving approach of an experienced center for interventional pulmonology.
Materials and methods: We retrospectively examined the records of 1307 patients who underwent a total of 2029 interventional
procedures in our interventional pulmonology department between January 2008 and December 2017.
Results: About half of the interventional procedures (47.2%) were performed on patients with airway stenosis due to malignant disease.
Among patients with benign airway stenosis, the most frequent reason for intervention was postintubation tracheal stenosis. The
number of patients who developed complications was 81 (6.2%), and the most common complication was hemorrhage (n = 31, 2.99%);
94.9% (n = 1240) of interventional procedures were performed under general anesthesia, without complications or deaths associated
with anesthesia. Only one death (0.076%) occurred in the perioperative period. A total of 18 patients (1.38%) died in the 30-day
perioperative and postoperative period. None of the patients with benign airway stenosis died.
Conclusion: Interventional bronchoscopy is an invasive but considerably safe and efficient procedure for selected cases and effective
treatment modality for airway obstructions, massive hemoptysis, and foreign body aspiration. Interventional pulmonology is a field
of pulmonary medicine that needs effort to progress and provide an opportunity to witness relevant developments, and increase the
number of competent physicians and centers.
Key words: Experience, progress, interventional pulmonology

1. Introduction
The first bronchoscopes used in medicine were rigid
bronchoscopes. Interventional bronchoscopy was first
performed by Gustav Killian in 1897. Dr. Killian used
bronchoscopy to successfully remove a bone from the
right main bronchus of a German farmer [1]. The rodlens telescope of the contemporary rigid bronchoscope
was developed by Harold Hopkins and modified to reach
its final design by Karl Storz [2]. Advances in the field of
bronchoscopy accelerated following the invention of the
flexible bronchoscopy by Shigeto Ikeda in the second half
of the 20th century [3]. Today, the main areas of application
of interventional bronchology are malignant airway
obstructions (MAO) primarily secondary to lung cancer,
and benign airway obstructions (BAO) resulting from
postintubation and posttracheostomy tracheal stenosis [4,5].

Additionally, bronchoscopic lung volume reduction
(BLVR) and transbronchial cryobiopsy (TBCB) are
additional applications of bronchoscopy which are
evolving [6,7]. The purpose of this study is to share our
10-year experience in interventional pulmonology. In
this regard, we tried to determine the range of procedures
performed, the demographic characteristics of patients,
and complication rates.
2. Materials and methods
2.1. Study design
The objective of this study was to retrospectively analyze the
data for the advanced interventional pulmonary procedures
we have performed over the last 10 years. The primary
objective was to examine the range of cases and interventions,
and to assess our complication and mortality rates.

* Correspondence: efsungoncachousein@yahoo.com
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2.2. Study population
Following approval of the local ethics committee,
we retrospectively examined the records of patients
between January 2008 and December 2017. Patients
who underwent interventional procedures in our
interventional pulmonology department were included
in the study. Our hospital is a tertiary referral center with
the highest patient volume in Turkey. Medical records
of all patients who underwent advanced bronchoscopic
intervention, medical thoracoscopy, or whole-lung
lavage therapy for pulmonary alveolar proteinosis were
recorded and reviewed. Bronchoscopic interventions
were assigned into two groups according to whether
rigid or fiberoptic bronchoscopic interventions were
used. The rigid bronchoscopic intervention group was
further divided into subgroups according to the primary
indications (malignant and benign airway obstructions,
foreign body aspiration, hemoptysis, etc.). For fiberoptic
bronchoscopic procedures, only patients who underwent
cryotransbronchial biopsy or who were treated with
bronchoscopic lung volume reduction were included in
the study. For each group, we recorded demographic data
such as patients’ age and sex, interventions performed,
number of procedures, and complication rates. Mortality
rates were calculated based on data of patients who died
perioperatively and within 30 days of the procedure. Patient
consent forms were obtained from all patients due to the
general practice of our hospital. Approval was obtained
from Yedikule Chest Diseases and Thoracic Surgery
Training and Research Hospital Scientific Committee with
the code: 2019: 226/3
2.3. Interventional procedures
Fiberoptic bronchoscopic procedures (BF-1TQ180 and
BF-XP 160, Olympus, Tokyo, Japan) were performed under
conscious sedation with a short-acting benzodiazepine
(midazolam). Rigid bronchoscopic procedures (Karl Storz,
Germany) were performed under general anesthesia (total
intravenous anesthesia), while medical thoracoscopic
procedures were performed with the same bronchoscope
under conscious sedation. In addition, fluoroscopy was
used for transbronchial cryobiopsy (TBCB) and coil
procedures. Midazolam (2–5 mg) was the anesthetic used
for bronchoscopic procedures done under conscious
sedation (moderate sedation). Following local anesthesia
of the oronasal airway with 10% lidocaine spray/gel, the
bronchoscope was inserted. When the nasal route was
not accessible, the oral route was used. Lidocaine 1%
was applied as needed throughout the procedure after
passing the glottis using the SAYGO (spray-as-you-go)
technique. All patients were routinely monitored with
electrocardiography and SpO2 during the procedure, with
arterial blood pressure measured every 5 min. General
anesthesia induction was achieved with midazolam
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0.05–0.10 mg/kg, propofol (maximum dose 1000 mg),
remifentanil (maximum dose 2 mg), and rocuronium
(maximum dose 50 mg), dosage given according to the
patient’s condition. We did not encounter any side effects
or complications due to anesthesia.
3. Results
3.1. General findings
Over the period of 10 years, the mean age of the study
population was 55.9 ± 14.4 with 74% (968) being male.
About half (47.2%) of the interventional procedures
were performed to treat malignant airway obstructions
(MAO). The lowest procedure rate of 1% was for patients
with stenosis following lung transplantation. Table
1 summarizes the distribution ratios of the patients
according to performed interventions and indications.
As for the demographic data, patients with
tracheobronchomalacia (TBM) had the highest average
age of 67.7 ± 11.5, while patients who were treated with
whole-lung lavage for pulmonary alveolar proteinosis
had the lowest average age of 34.8 ± 8.7. Patients with
posttracheostomy tracheal stenosis (PTTS) had the highest
rate of procedures per case (2.88 ± 3.01). While 94.9% (n
= 1240) of interventional procedures were performed
under general anesthesia, only endobronchial valves and
medical thoracoscopy (MT) procedures were performed
under conscious sedation with midazolam. Endobronchial
stents were placed only for airway obstructions of either
malignant or benign etiology. There were 851 patients in
these two groups, of whom 283 (33.25%) received stent
placement; the majority of stents (73.1% vs 26.9%) were
placed in patients with malignant airway obstruction
(Table2).
The complication rate was 6.2% (n = 81) for the entire
study population, with the most common complication
being hemorrhage with a rate of 2.99% (n = 31). A total of 18
patients died and the 30-day peri-/postoperative mortality
rate was found to be 1.38%. While interventions performed
by rigid bronchoscopy for malignant or benign disorders
had a complication rate of 4.59%, most deaths occurred in
the patients who underwent interventional procedures for
MAO. One of the patients with nonsmall cell lung cancer
died perioperatively from cardiac arrest and 15 patients
died from severe respiratory failure while being treated
in the intensive care unit. Only 2 deaths resulted from the
remaining procedures. One patient died from massive
hemoptysis on the eighth day after coil placement, and the
second patient died from respiratory failure resulting from
primary disease progression (Table 3).
3.2. Malignant airway obstructions
A total of 617 patients underwent 953 interventional
procedures for MAO. This group of patients had a
complication rate of 7.3% and a mortality rate of 2.59%.
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Table 1. Distribution of interventional procedures according to indications.
Indications

n (%)
Malignant
stenosis

Procedures with
rigid bronchoscopy

Fiber optic
bronchoscopy (FOB)
Other

Benign stenosis

Malignant airway obstructions (MAO) secondary to lung carcinomas

550 (42.08)

MAO secondary to endobronchial metastasis/invasion

67 (5.12)

Airway obstruction secondary to benign tumors

46 (3.52)

Postintubation tracheal stenosis (PITS)

111 (8.5)

Fibrostenosis

20 (1.53)

Posttransplantation stenosis

13 (1)

Tracheobronchomalacia (TBM)

18 (1.38)

Posttracheostomy tracheal stenosis (PTTS)

26 (1.99)

Diagnostic bronchoscopy

144 (11.02)

Hemoptysis

106 (8.11)

Foreign body aspiration

35 (2.67)

Transbronchial cryobiopsy (TBCB)

50 (3.82)

Bronchoscopic lung volume reduction (BLVR) (EBV and coil)

67 (5.13)

Medical thoracoscopy (MT)

37 (2.83)

Pulmonary alveolar proteinosis (PAP)

17 (1.3)

Total

1307 (100)

Table 2. Demographic features of the study population.
n

Age (Year)

Female
/ Male

Number of
procedures

Procedure
Type of
Number
number per case anesthesia of stents %

Lung tumors

550

58.0 ± 11.8

82/468

834

1.51 ± 1.06

GA

176/32

Metastasis/ invasion

67

58.7 ± 14.2

34/33

119

1.77 ± 1.27

GA

31/46.3

Benign tumors

46

53.2 ± 15

11/35

82

1.78 ± 1.28

GA

…

Postintubation tracheal
stenosis (PITS)

111

53.4 ± 17

54/57

281

2.51 ± 2.56

GA

50/46.8

Fibrostenosis

20

44.2 ± 10.5

6/14

54

2.70 ± 3.37

GA

6/30

Posttransplantation
stenosis

13

42.7 ± 16.3

2/11

25

1.92 ± 1.11

GA

3/2.3

Tracheobronchomalacia

18

67.7 ± 11.5

7/11

46

2.55 ± 1.75

GA

1583.4

Posttracheostomy
tracheal stenosis

26

55 ± 14.5

12/14

75

2.88 ± 3.01

GA

20.8

Interventional diagnostic bronchoscopies 144

58.4 ± 13.9

43/101

164

1.32 ± 0.47

GA

…

Hemoptysis

106

52.8 ± 16.9

20/86

106

1

GA

…

Foreign body aspiration

35

50.3 ± 19.7

13/22

35

1

GA

…

Transbronchial cryobiopsy

59

53.5 ± 13.7

30/20

59

1

GA

…

Bronchoscopic lung volume reduction

67

62.8 ± 7.3

7/60

67

1

GA*/MS

…

Medical thoracoscopy

37

50.94 ± 15.38 11/26

37

1

MS

…

Pulmonary alveolar proteinosis

17

34.8 ± 8.7

45

2.64 ± 1.45

GA

...

Categories
Malignant
stenosis

Benign
stenosis

7/10

Abbreviations: PITS = Postintubation tracheal stenosis, PTTS = Posttracheostomy Tracheal stenosis, TBM = Tracheobronchomalacia,
FBA = Foreign body aspiration, PAP = Pulmonary alveolar proteinosis. BLVR = Bronchoscopic lung volume reduction, TBCB =
Transbronchial cryobiopsy, MT = Medical thoracoscopy, GA = General anesthesia, MS = Moderate sedation, *Coil procedure.
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Pulmonary malignancies were the most common cause
of MAO (Figures 1 and 2). The histopathological results
of 27 patients who were referred to our center from
different centers were not available for review. The most
common diagnosis (42.3%) of patients whose pathology
reports were available was squamous cell lung carcinoma
(Table 4). Regarding the serious complications of the
procedure, 1 patient died of perioperative cardiac arrest,
8 patients required admission to the intensive care unit
because of prolonged intubation after the procedure, and
15 of these patients died within a month. There were 119
interventional procedures performed on 67 patients with

airway obstruction secondary to endobronchial metastasis
or invasion of extrapulmonary malignancies. The most
frequent causes of MAO in these patients were esophageal,
thyroid, and renal cell carcinomas. Procedure-related
complications were seen in 7 patients, the most serious
being prolonged bleeding in a patient with renal cell
carcinoma. None of these patients died perioperatively or
in the early postoperative period.
3.3. Benign airway obstructions
Two hundred thirty-four patients with benign airway
obstruction (BAO) underwent rigid bronchoscopy
under general anesthesia. Of them 46 had benign

Table 3. Procedures with complications and 30-day mortality rates.
Complications

Malignant
stenosis

Benign
stenosis

Bronchoscopic lung
volume reduction (BLVR)

Medical
thoracoscopy (MT)

Transbronchial
Cryobiopsy (TBCB)

Hemorrhage, %

14/2.26

2/8.5

…

…

15/30

Arrhythmias, %

12/1.95

5/2.1

…

…

…

Prolonged intubation duration, %

3/0.48

…

…

…

…

Pneumothorax (Px), %

…

…

…

…

6/12

Exitus, %

16*/2.59

…

1/1.5

…

1/2

Others

…

…

…

6

…

Total, %

52/4.59

29/17.0

Figure 1. Malignant airway obstruction (MAO) in left and right main bronchus, before and after endobronchial therapy and silicone
Y-stent application.

Figure 2. MAO in the trachea secondary to malignant melanoma, before and after endobronchial therapy poliflex stent insertion.
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Table 4. Histopathologic types and percentages of lung tumors.
Histopathogy

n (%)

Squamous cell carcinoma

221 (42.3%)

Nonsmall cell lung carcinoma

151 (28.9%)

Small cell lung carcinoma

47 (9.0%)

Adenocarcinoma

39 (7.5%)

Carcinoid tumor

45 (8.6%)

Adenoid cystic carcinoma

6 (1.1%)

Carcinoma in-situ

4 (0.8%)

Low differentiated carcinoma

3 (0.6%)

Malignant mesenchimal tumor

3 (0.6%)

Low grade neuroendocrine tumor

2 (0.4%)

High grade neuroendocrine tumor

1 (0.2%)

Papillary malignant epithelial tumor

1 (0.2%)

Total

523 (100.0%)

* Pathology reports of 27 patients could not be found.

tumors, 111 had postintubation tracheal stenosis, 20 had
fibrostenosis, 13 had posttransplantation stenosis, 18 had
tracheobronchomalacia, and 26 had posttracheostomy
tracheal stenosis (Table 2). Among all BAO, debulking
and subsequent histopathological evaluation revealed 46
benign tumors. Of these, the most common diagnosis
was hamartoma (30.4%). During the period of 10 years,
there were 281 procedures performed on 111 patients
with postintubation tracheal stenosis (PITS), the number
of procedures per patient averaging 2.51 ± 2.56. The
average duration of symptoms before treatment was 7 ±
6.9 weeks and the average duration of intubation was 15.2
± 9.3 days. Eighty-four patients (75.7%) had complextype stenotic lesions (Figures 3 and 4). Fifty patients
(46.8%) were treated with stent implantation, the most
preferred (96%) type being the stenotic tracheal stent. No
complications were observed related to the interventions.
The highest numbers of procedures per patient were
performed on the group of patients with PTTS. In this
group, 75 interventional procedures were performed
on 26 patients (average number of procedures per case
2.88 ± 3.01) without any complications. Other causes of
benign stenosis were fibrostenosis at the anastomosis line
following surgery in 20 patients, stenosis following lung
transplantation in 13 patients, and 18 patients who had
been operated on for tracheobronchomalacia. None of
the patients who underwent interventional procedures for
benign airway obstruction died.
3.4. Medical thoracoscopy (MT)
A total of 37 patients (26 M, 11 F) underwent diagnostic
MT. These patients had a failed diagnosis by classical

methods, including thoracentesis and closed pleural
biopsy, before medical thoracoscopy. Among all patients,
the diagnoses were pleural effusion due to tuberculosis (n
= 13), malignant pleural mesothelioma (n = 5), nonsmall
cell lung cancer metastasis (n = 2), small cell lung cancer
metastasis (n = 1), breast cancer metastasis (n = 1), renal cell
cancer metastasis (n = 2), larynx cancer metastasis (n = 1),
primary pleural B-cell lymphoma (n = 1), benign pleural
asbestosis (n = 1), and finally, chronic nonspecific pleuritis
(n = 9). In one patient, a diagnosis was not achieved after
MT. The complications rate was 19% (n = 7). Four patients
had subcutaneous emphysema and 3 patients required
chest tube drainage for lung nonexpansion. One patient
with prolonged air leakage died on day 34 postintervention
secondary to severe respiratory failure.
3.5. Transbronchial cryobiopsy (TBCB)
Transbronchial cryobiopsy (TBCB) was performed on
59 patients with an adequate pathologic specimen being
obtained in 96%. A cryoprobe with a 1.9-mm external
diameter was used. Biopsy was performed during general
anesthesia and under fluoroscopic guidance. Biopsy
material obtained had a mean tissue surface area of 31.8 ±
16 mm². One patient died (2%) following TBCB secondary
to progression of his/her primary disease. The most
common complications were pneumothorax requiring
chest tube placement in 6 (12%) patients and hemorrhage
in 15 patients (30%). Hemorrhage was graded according
to the amount of bleeding and endoscopic procedures
required to control bleeding [8]. Among patients who
developed hemorrhage, 8 (53.3%) patients had grade I and
7 (46.7%) patients had grade II hemorrhage.
3.6. Bronchoscopic lung volume reduction (BLVR): endobronchial valve (EBV) and coil treatments
A total of 67 patients underwent BLVR interventions
(30 patients had EBV and 37 had coil treatment). EBV
procedures were performed under conscious anesthesia
with midazolam, and coil procedures were performed
under general anesthesia with fluoroscopic guidance. The
most important intervention-associated complication was
the development of massive hemoptysis in 1 patient on the
eighth day following coil treatment. This patient died of
asphyxia secondary to hemoptysis.
3.7. Other procedures
One hundred fourteen patients underwent diagnostic rigid
bronchoscopy either because fiberoptic bronchoscopy was
nondiagnostic or because a high bleeding risk precluded
biopsy. Thirty-five patients underwent foreign body
aspiration and 17 patients were treated with whole-lung
lavage for pulmonary alveolar proteinosis. A total of 106
patients underwent rigid bronchoscopy for hemoptysis
evaluation. Of them, the majority of patients had
endobronchial malignancies. Among these patients, none
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Figure 3. Benign airway obstruction (BAO), complex type tracheal stenosis, after mechanical
dilation and silicone tracheal stenotic stent application.

Figure 4. BAO secondary to pulmonary amiloidoma on the main carina after endobronchial therapy, and view after 5 months follow-up.

developed complications or died perioperatively or in the
early postoperative period.
4. Discussion
In this retrospective study we presented our 10-year
experiences in interventional bronchoscopy. During this
period, 2029 interventional procedures were performed
on 1307 patients; 81 patients suffered complications,
corresponding to a rate of 6.2%. Eighteen patients died,
with 30-day mortality being 1.38%.
Lung cancer is the most common cause of MAO [9].
The majority of patients operated for malignant airway
obstruction in our case series had lung cancer (seen
in Table 1). A total of 953 interventional procedures
were performed on 617 patients, with a complication
rate of 7.3% and 30-day mortality of 2.59%. In their
multicenter prospective study, Ernst et al. reported that the
complication rate and 30-day mortality of 554 therapeutic
procedures were 19.8% and 7.8%, respectively [10]. Among
253 patients with MAO, one died during the procedure,
while 42% of cases were operated on on an emergent basis.
In a study on therapeutic bronchoscopy for MAO with the
participation of 15 centers, 1115 interventional procedures
were performed on 947 patients; the complication rate
was reported as 3.9%. However, the rate of complications

1460

differed to a great extent (from 0.9% to 11.7%) between
centers. Consistent with our experience, 30-day mortality
averaged 14.8%, with a range of 7.7% to 20.2% among
the different centers [10,11]. The other group consisted
of the patients with airway obstruction secondary to
benign tumors. The majority of these patients had
hamartoma, which is the most common benign tumor of
the lungs [12]. The most frequent causes of benign airway
obstruction were PITS and PTTS [13,14]. Likewise, in our
series, patients with airway stenosis due to PTTS and PITS
received the highest number of interventions and had the
highest rate of interventions per patient. This was the result
of the need for recurrent dilations and frequent follow-ups
[10]. Our study included 301 patients who were treated
for benign airway obstruction; of these, 22.2% had PITS
and 83.6% were found to have complex types of tracheal
stenosis.
In our series, 281 interventional procedures were
performed on 111 patients with PITS. Similarly, 84%
of our patients had complex types of tracheal stenosis.
Another patient group with a benign disorder causing
airway obstruction was lung transplantation patients
with stenosis developing at the anastomosis line; 25
interventional procedures were performed on 13 such
patients without any complications. Studies have reported

ÖZGÜL et al. / Turk J Med Sci
that stenosis at the anastomosis line is the most frequent
complication developing in lung transplant patients, with
rates of 13%–16% [15,16].
Life-threatening hemoptysis has been reported in
5%–15% of cases [17]. Mortality from massive hemoptysis
ranges from 9% to 38%, the highest rate being reported
in patients with advanced lung cancer [18]. A bleeding
focus was identified and controlled successfully in
61.3% of patients who underwent rigid bronchoscopy
for hemoptysis. In these patients, the most commonly
observed etiology was endobronchial malignancy.
Bronchoscopic examination accurately identified the
bleeding focus in 73%–93% of patients with hemoptysis
[19]. In experienced centers, rigid bronchoscopy is the
intervention of choice because it confers advantages such
as securing the airway and providing for ventilation,
especially in the presence of massive hemoptysis, it has
a stronger aspiration capacity thanks to its wide working
channel, and allows the simultaneous use of a fiberoptic
bronchoscope in order to reach the distal airways [20].
Medical thoracoscopy is a safe procedure with low
mortality rate (0.35%) in experienced hands [21]. We
encountered 4 cases of subcutaneous emphysema and 3
cases of prolonged air leakage. None of our patients had
lung laceration, but one of the patients with prolonged
air leakage died of respiratory failure 34 days after the
procedure. In a study on the safety and complications
of MT, the rate of nonserious complications was 16.5%,
the most frequent being prolonged air leakage and fever,
and there was no operative mortality. The most serious
complication, pulmonary laceration, was encountered in
3 patients, leading the authors to conclude that better case
management is needed for these patients [22].
The classical treatment of pulmonary alveolar
proteinosis (PAP) is whole-lung lavage performed under
general anesthesia and selective intubation [23]. As
it carries a low risk of life-threatening complications,
this method is considered a safe and effective treatment
option in the management of PAP. The most frequent
complication related to the procedure was reported to be
transient elevation of temperature (18%), and the risk of
pneumothorax was considerably low (0.8%) [24]. On the
other hand, in a study with 12 participating centers, 11 of 33
patients (33%) undergoing whole-lung lavage experienced
complications, the most common being oxygen
desaturation. The same study reported that 2 patients died;
one PAP patient secondary to myelodysplastic syndrome,
and the other due to disease-associated adults’ respiratory
distress syndrome (ARDS) [25]. We did not observe any
perioperative or early postoperative complications in a
total of 45 operations performed on 17 patients.
Pneumothorax and hemorrhage are the most
frequently observed complications of TBCB [26]. A

metaanalysis of data from 994 participants in 15 studies
reported an average pneumothorax rate of 10% [27]. In
another metaanalysis of 13 studies, the same rate was
found to be 9.5% (5.9%–14.9%). Generally, the rates of
pneumothorax, bleeding, and 30-day mortality following
TBCB are reported to be 0%–26%, 0%–42%, and <2%,
respectively; in our patient series, the respective rates were
12%, 30%, and 2% [28].
In recent years, we have witnessed many new
developments and expanding applications in the field
of interventional pulmonology. In the last 10 years,
the number of procedures performed by our team has
increased along with our experience, and our approach
has evolved as new procedures have become available.
When considering our data, we saw that our approach
to patients with tracheomalacia during this time period
has evolved from stent placement towards CPAP titration,
which is less invasive.
We also noticed that in the last 5 years of the study
period, we have predominantly used silicon stents instead
of metallic ones because of fewer complications and
increased ease of removal.
In the last years, increased cost awareness has resulted
in the use of domestically produced stents. Although their
placement is more difficult and time consuming than that
of original stents, our increasing experience has mitigated
this problem.
While LASER was used more frequently in the first
years of our study, APC, being cost effective and efficient,
has been used increasingly more often during the latter
years and has become as efficient and safe as LASER in
regard to bleeding control and coagulation.
BLVR and TBCB are becoming routinely performed
procedures, and with increasing experience we obtain
better results.
Our team of physicians follow up with the patients
according to predetermined charts and are able to detect
and treat complications early.
We support the training of physicians from other
centers in order to increase the number of patients that
can benefit from interventional pulmonology.
The most important limitations of this study are
its retrospective nature and, despite a large number of
patients, being a single-center study. Nonetheless, with the
high patient volume we believe that it contributes to the
current English literature and gives valuable information
regarding interventional pulmonology.
In conclusion, with the present study we have shared
our 10 years of experience, evolving approaches, and the
inclusion of new modalities in the field of interventional
pulmonology.
Although
invasive,
interventional
bronchoscopy is a safe and efficient procedure for
selected cases, especially in experienced hands. It is an
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excellent treatment modality both for airway obstructions
developing secondary to malignancies, particularly lung
cancer, and for life threatening conditions such as massive
hemoptysis and foreign body aspiration.
Interventional pulmonology is a field of pulmonary
medicine that should not be overlooked. Efforts should

be made to advance this field and to increase the number
of competent physicians and centers. We consider that
disclosing practical experiences in this area of pulmonary
medicine will both spark interest in interventional
pulmonology and will provide an opportunity to witness
relevant developments.
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